Literature DB >> 9559487

Change in major amputation rate in a center dedicated to diabetic foot care during the 1980s: prognostic determinants for major amputation.

E Faglia1, F Favales, A Aldeghi, P Calia, A Quarantiello, P Barbano, M Puttini, B Palmieri, G Brambilla, A Rampoldi, E Mazzola, L Valenti, G Fattori, V Rega, A Cristalli, G Oriani, M Michael, A Morabito.   

Abstract

From 1990 to 1993, 115 diabetic patients were consecutively hospitalized in our diabetologic unit for foot ulcer and 27 (23.5%) major amputations were carried out. The major amputation rate of this series of cases was compared with that occurring in diabetic subjects taken into our hospital for foot ulcer in two previous periods: 1979-1981 (17 major amputations in 42 inpatients or 40.5%) and 1986-1989 (26 major amputations in 78 inpatients or 33.3%). The comparison shows a progressive reduction in major amputation rate [Odds ratio 0.66, 95% confidence interval (CI) 0.46-0.96]. Univariate and multivariate analysis, carried out in the population of the 1990-1993 period, in order to detect the independent factors associated with major amputation show the following prognostic determinants of major amputation: Wagner grade (odds ratio 7.69, CI 1.58-37.53), prior stroke (odds ratio 35.05, CI 3.14-390.53), prior major amputation (odds ratio 3.49, CI 1.26-9.38), transcutaneous oxygen level (odds ratio 1.06, CI 1.01-1.12), and ankle-brachial blood pressure index (odds ratio 4.35, CI 1.58-12.05), while an independent protective role was attributed to hyperbaric oxygen treatment (odds ratio 0.15, CI 0.03-0.64). In accordance with other studies, we, therefore, conclude that a comprehensive protocol as well as a multidisciplinary approach in a dedicated center can assure a decrease in major amputation rate. The parameters of limb perfusion were the modifiable prognostic determinants most strongly predictive for amputation.

Entities:  

Mesh:

Year:  1998        PMID: 9559487     DOI: 10.1016/s1056-8727(97)98004-1

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  13 in total

1.  A retrospective study of diabetic foot ulcers treated with hyperbaric oxygen therapy.

Authors:  Alexandra J Bishop; Elizabeth Mudge
Journal:  Int Wound J       Date:  2012-02-28       Impact factor: 3.315

Review 2.  Hyperbaric oxygen, vasculogenic stem cells, and wound healing.

Authors:  Katina M Fosen; Stephen R Thom
Journal:  Antioxid Redox Signal       Date:  2014-05-19       Impact factor: 8.401

Review 3.  Hyperbaric oxygen: its mechanisms and efficacy.

Authors:  Stephen R Thom
Journal:  Plast Reconstr Surg       Date:  2011-01       Impact factor: 4.730

Review 4.  Diabetic foot screening: why is it neglected?

Authors:  Ma'en Zaid Abu-Qamar
Journal:  Int Wound J       Date:  2006-09       Impact factor: 3.315

Review 5.  Diabetic foot wounds: the value of negative pressure wound therapy with instillation.

Authors:  Luca Dalla Paola
Journal:  Int Wound J       Date:  2013-12       Impact factor: 3.315

Review 6.  Diabetic foot ulcers treated with hyperbaric oxygen therapy: a review of the literature.

Authors:  Alexandra J Bishop; Elizabeth Mudge
Journal:  Int Wound J       Date:  2012-07-02       Impact factor: 3.315

7.  Comprehensive approach to management of critical limb ischemia.

Authors:  Lanfroi Graziani
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09

8.  Can major amputation rates be decreased in diabetic foot ulcers with hyperbaric oxygen therapy?

Authors:  Ahmet Kaya; Figen Aydin; Taskin Altay; Levent Karapinar; Hasan Ozturk; Cengiz Karakuzu
Journal:  Int Orthop       Date:  2008-07-25       Impact factor: 3.075

Review 9.  Clinical Effectiveness of Hyperbaric Oxygen Therapy in Complex Wounds.

Authors:  Supaporn Opasanon; Warut Pongsapich; Sitthichoke Taweepraditpol; Bhoom Suktitipat; Apirag Chuangsuwanich
Journal:  J Am Coll Clin Wound Spec       Date:  2015-04-09

10.  Adjunct methods of the standard diabetic foot ulceration therapy.

Authors:  Dariusz Waniczek; Andrzej Kozowicz; Małgorzata Muc-Wierzgoń; Teresa Kokot; Elżbieta Swiętochowska; Ewa Nowakowska-Zajdel
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.